Unsupported Browser
The American College of Surgeons website is not compatible with Internet Explorer 11, IE 11. For the best experience please update your browser.
Menu
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
ACS
Bulletin

Coming next month in JACS and online now: Outcomes of resectability assessment of the Dutch Colorectal Cancer Group Liver Metastases Expert Panel

Researchers report that the high rate of disagreement among experienced liver surgeons reflects the complexity in defining treatment strategies for colorectal cancer liver metastases.

ACS

November 1, 2019

Joost Huiskens, MD; Karen Bolhuis, MD; Marc R. W. Engelbrecht, MD, PhD; and colleagues in the December issue of the Journal of the American College of Surgeons (JACS) analyzed prospective resectability evaluation of patients with colorectal cancer liver metastases (CRLM) by a panel of radiologists and liver surgeons and found that the high rate of disagreement among experienced liver surgeons reflects the complexity in defining treatment strategies for CRLM and supports the use of a panel rather than a single-surgeon decision.

This article and all other JACS content is available on the JACS website.